Previous 10 | Next 10 |
IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported the first utilization in Europe of its Version 2.0 software, together with the ClearPoint Neuro ...
ClearPoint Neuro (CLPT) reports Q4 preliminary revenue of ~$3.7M, up 14% Y/Y. Consensus revenue of $3.29M.FY20 preliminary revenue will be ~$12.8M, up 14% Y/Y. Consensus revenue of $12.4M.The Company supported 175 cases in Q4 against the backdrop of continued postponements of elective procedu...
IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported preliminary unaudited revenue results for the quarter and full yea...
Click here to read the previous top NASDAQ medical device stocks article. The growing prevalence of chronic diseases such as cancer and diabetes is driving increasing innovation in medical device technology . As of mid-December 2020, 49 new devices had been approve...
ClearPoint Neuro (CLPT) amends its January 2020 secured convertible note financing agreement with Petrichor Healthcare Capital Management and PTC Therapeutics, thereby providing an additional $7.5M strategic investment from Petrichor and improving terms relative to the original conversion pri...
IRVINE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an amendment to its January 2020 secured convertible note financi...
IRVINE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a leader in image-guided stereotactic neurosurgery, announced that its 4,000 th neurosurgical procedure using the ClearPoint Neuro Navigation System was completed earlier this month at Dartmouth-Hit...
ClearPoint Neuro, Inc. (CLPT) Q3 2020 Earnings Conference Call November 11, 2020 16:30 ET Company Participants Joe Burnett - Chief Executive Officer Harold Hurwitz - Chief Financial Officer Conference Call Participants Andrew D'Silva - B. Riley FBR Sall Yanchus - Brookline Capital Markets Hen...
ClearPoint Neuro (CLPT): Q3 GAAP EPS of -$0.09 beats by $0.06.Revenue of $3.52M (+20.1% Y/Y) beats by $1.32M.Press Release For further details see: ClearPoint Neuro EPS beats by $0.06, beats on revenue
IRVINE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a medical device company with a portfolio of products focused on enabling therapies for neurological disorders, today announced financial results for its third fiscal quarter ended September 30, 2020. ...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
ClearPoint Neuro, Inc. Website:
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its ...
2024-07-15 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...